Moreover, many studies have demonstrated that gene mutations in the EGFR downstream signal pathways, such as the RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways, are also significantly important in relation to the response to EGFR-TKI treatment in patients with NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.